Signal Transduction and Targeted Therapy (Apr 2022)

WT-PE: Prime editing with nuclease wild-type Cas9 enables versatile large-scale genome editing

  • Rui Tao,
  • Yanhong Wang,
  • Yun Hu,
  • Yaoge Jiao,
  • Lifang Zhou,
  • Lurong Jiang,
  • Li Li,
  • Xingyu He,
  • Min Li,
  • Yamei Yu,
  • Qiang Chen,
  • Shaohua Yao

DOI
https://doi.org/10.1038/s41392-022-00936-w
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Large scale genomic aberrations including duplication, deletion, translocation, and other structural changes are the cause of a subtype of hereditary genetic disorders and contribute to onset or progress of cancer. The current prime editor, PE2, consisting of Cas9-nickase and reverse transcriptase enables efficient editing of genomic deletion and insertion, however, at small scale. Here, we designed a novel prime editor by fusing reverse transcriptase (RT) to nuclease wild-type Cas9 (WT-PE) to edit large genomic fragment. WT-PE system simultaneously introduced a double strand break (DSB) and a single 3′ extended flap in the target site. Coupled with paired prime editing guide RNAs (pegRNAs) that have complementary sequences in their 3′ terminus while target different genomic regions, WT-PE produced bi-directional prime editing, which enabled efficient and versatile large-scale genome editing, including large fragment deletion up to 16.8 megabase (Mb) pairs and chromosomal translocation. Therefore, our WT-PE system has great potential to model or treat diseases related to large-fragment aberrations.